Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration

Journal of Neuroscience

Volumn 27, Issue 51, 2007, Pages 13997-14006

  Chinta, Shankar J ^a   Kumar, M J ^a   Hsu, Michael ^a   Rajagopalan, Subramanian ^a   Kaur, Deepinder ^a   Rane, Anand ^a   Nicholls, David G ^a   Choi, Jinah ^b   Andersen, Julie K ^a,c  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

Dopaminergic neuron; Glutathione; Mitochondrial complex I; Parkinson's disease; S nitrosation; Substantia nigra

Indexed keywords

DOPAMINE; GAMMA GLUTAMYL CYSTEINE LIGASE; GLUTATHIONE; GLUTATHIONE DISULFIDE; LIGASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATECHOLAMINE NERVE CELL; CELL COUNT; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GLUTATHIONE METABOLISM; IMMUNOGOLD ELECTRON MICROSCOPY; IMMUNOHISTOCHEMISTRY; MESENCEPHALON; MOUSE; NIGRONEOSTRIATAL SYSTEM; NITROSATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRIATONIGRAL DEGENERATION; SYNAPTOSOME; TRANSGENIC MOUSE; WESTERN BLOTTING; AGE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL SURVIVAL; COMPARATIVE STUDY; CORPUS STRIATUM; GENETICS; METABOLISM; NERVE CELL; NERVE DEGENERATION; PATHOLOGY; PHYSIOLOGY; SUBSTANTIA NIGRA;

AGE FACTORS; ANIMALS; CELL SURVIVAL; CORPUS STRIATUM; DOPAMINE; GLUTATHIONE; MESENCEPHALON; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NERVE DEGENERATION; NEURONS; SUBSTANTIA NIGRA;

EID: 38449097902     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.3885-07.2007     Document Type: Article

References (51)

1. Andersen JK (2006) Translational and post-translational modifications to mitochondrial complex I in the post-mortem Parkinsonian midbrain. Paper presented at post-genomic symposium, Beijing, China, May.
2. Andersen JK, Mo JQ, Hom DG, Lee FY, Harnish P, Hamill RW, McNeill TH (1996) Effect of buthionine sulfoximine, a synthesis inhibitor of the antioxidant glutathione, on the murine nigrostriatal neurons. J Neurochem 67:2164-2171.
3. Bannon MJ, Goedert M, Williams B (1984) The possible relation of glutathione, melanin and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) to Parkinson's disease. Biochem Pharmacol 33:2697-2698.
4. Bharath S, Hsu M, Kaur D, Rajagopalan S, Andersen JK (2002) Glutathione, iron and Parkinson's disease. Biochem Pharmacol 64:1037-1048.
5. Bolanos JP, Heales SJ, Peuchen S, Barker JE, Land JM, Clark JB (1996) Nitric oxide-mediated mitochondrial damage: a potential neuroprotective role for glutathione. Free Radic Biol Med 21:995-1001.
6. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
7. Budd DC, Nicholls DG (1995) Protein kinase C-mediated suppression of the presynaptic adenosine A1 receptor by a facilitatory metabotropic glutamate receptor. J Neurochem 65:615-621.
8. Burwell LS, Nadtochiy SM, Tompkins AJ, Young S, Brookes PS (2006) Direct evidence for S-nitrosation of mitochondrial complex I. Biochem J 394:627-634.
9. Chinta SJ, Andersen JK (2006) Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease. Free Radic Biol Med 41:1442-1448.
10. Chinta SJ, Rajagopalan S, Butterfield DA, Andersen JK (2006) In vitro and in vivo neuroprotection by gamma-glutamylcysteine ethyl ester against MPTP: relevance to the role of glutathione in Parkinson's disease. Neurosci Lett 402:137-141.
11. Choi J, Liu RM, Kundu RK, Sangiorgi F, Wu W, Maxson R, Forman HJ (2000) Molecular mechanism of decreased glutathione content in human immunodeficiency virus type 1 Tat-transgenic mice. J Biol Chem 275:3693-3698.
12. Clementi E, Brown GC, Feelisch M, Moncada S (1998) Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci USA 95:7631-7636.
13. Cook JA, Kim SY, Teague D, Krishna MC, Pacelli R, Mitchell JB, Vodovotz Y, Nims RW, Christodoulou D, Miles AM, Grisham MB, Wink DA (1996) Convenient colorimetric and fluorometric assays for S-nitrosothiols. Anal Biochem 238:150-158.
14. Cooper AJ, Pulsinelli WA, Duffy TE (1980) Glutathione and ascorbate during ischemia and postischemic reperfusion in rat brain. J Neurochem 35:1242-1245.
15. Dahm CC, Moore K, Murphy MP (2006) Persistent S-nitrosation of complex I and other mitochondrial membrane proteins by S-nitrosothiols but not nitric oxide or peroxynitrite: implications for the interaction of nitric oxide with mitochondria. J Biol Chem 281:10056-10065.
16. Dalton TP, Chen Y, Schneider SN, Nebert DW, Shertzer HG (2004) Genetically altered mice to evaluate glutathione homeostasis in health and disease. Free Radic Biol Med 37:1511-1526.
17. Diaz-Hernandez JI, Almeida A, Delgado-Esteban M, Fernandez E, Bolanos JP (2005) Knockdown of glutamate-cysteine ligase by small hairpin RNA reveals that both catalytic and modulatory subunits are essential for the survival of primary neurons. J Biol Chem 280:38992-39001.
18. Docherty M, Bradford HF, Cash CD, Ehret M, Maitre M, Joh TH (1991) Isolation of monoaminergic synaptosomes from rat brain by immunomagnetophoresis. J Neurochem 56:1569-1580.
19. Dringen R (2000) Metabolism and functions of glutathione in brain. Prog Neurobiol 62:649-671.
20. Dringen R, Hirrlinger J (2003) Glutathione pathways in the brain. Biol Chem 384:505-516.
21. Dringen R, Pfeiffer B, Hamprecht B (1999) Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. J Neurosci 19:562-569.
22. Ehrhart J, Zeevalk GD (2001) Hydrogen peroxide removal and glutathione mixed disulfide formation during metabolic inhibition in mesencephalic cultures. J Neurochem 77:1496-1507.
23. Ehrhart J, Zeevalk GD (2003) Cooperative interaction between ascorbate and glutathione during mitochondrial impairment in mesencephalic cultures. J Neurochem 86:1487-1497.
24. Fariss MW, Reed DJ (1987) High-performance liquid chromatography of thiols and disulfides: dinitrophenol derivatives. Methods Enzymol 143:101-109.
25. Fitzmaurice PS, Ang L, Guttman M, Rajput AH, Furukawa Y, Kish SJ (2003) Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease. Mov Disord 18:969-976.
26. Gow AJ, Chen Q, Hess DT, Day BJ, Ischiropoulos H, Stamler JS (2002) Basal and stimulated protein S-nitrosylation in multiple cell types and tissues. J Biol Chem 277:9637-9640.
27. Greco TM, Hodara R, Parastatidis I, Heijnen HF, Dennehy MK, Liebler DC, Ischiropoulos H (2006) Identification of S-nitrosylation motifs by site-specific mapping of the S-nitrosocysteine proteome in human vascular smooth muscle cells. Proc Natl Acad Sci USA 103:7420-7425.
28. Heales SJ, Davies SE, Bates TE, Clark JB (1995) Depletion of brain glutathione is accompanied by impaired mitochondrial function and decreased N-acetyl aspartate concentration. Neurochem Res 20:31-38.
29. Hogan B, Costantini F, Lacy E (1986) Manipulating the mouse embryo. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
30. Hsu M, Srinivas B, Kumar J, Subramanian R, Andersen J (2005) Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: implications for Parkinson's disease. J Neurochem 92:1091-1103.
31. Huang CS, Chang LS, Anderson ME, Meister A (1993) Catalytic and regulatory properties of the heavy subunit of rat kidney gamma-glutamylcysteine synthetase. J Biol Chem 268:19675-19680.
32. Jain A, Martensson J, Stole E, Auld PA, Meister A (1991) Glutathione deficiency leads to mitochondrial damage in brain. Proc Natl Acad Sci USA 88:1913-1917.
33. Jenner P (1993) Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand Suppl 146:6-13.
34. Jha N, Jurma O, Lalli G, Liu Y, Pettus EH, Greenamyre JT, Liu RM, Forman HJ, Andersen JK (2000) Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease. J Biol Chem 275:26096-26101.
35. Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, Viswanath V, Jacobs R, Yang L, Beal MF, DiMonte D, Volitaskis I, Ellerby L, Cherny RA, Bush AI, Andersen JK (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37:899-909.
36. Martinez M, Ferrandiz ML, Diez A, Miquel J (1995) Depletion of cytosolic GSH decreases the ATP levels and viability of synaptosomes from aged mice but not from young mice. Mech Ageing Dev 84:77-81.
37. McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, Di Monte DA (2002) Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 10:119-127.
38. Meister A (1988) Glutathione metabolism and its selective modification. J Biol Chem 263:17205-17208.
39. Meister A (1995) Glutathione biosynthesis and its inhibition. Methods Enzymol 252:26-30.
40. Nadtochiy SM, Burwell LS, Brookes PS (2007) Cardioprotection and mitochondrial S-nitrosation: effects of S-nitroso-2- mercaptopropionyl glycine (SNO-MPG) in cardiac ischemia-reperfusion injury. J Mol Cell Cardiol 42:812-825.
41. Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD (1997) Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm 104:661-677.
42. Perry TL, Yong VW (1986) Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 67:269-274.
43. Schilling B, Bharath MMS, Row RH, Murray J, Cusack MP, Capaldi RA, Freed CR, Prasad KN, Andersen JK, Gibson BW (2005) Rapid purification and mass spectrometric characterization of mitochondrial NADH dehydrogenase (Complex I) from rodent brain and a dopaminergic neuronal cell line. Mol Cell Proteomics 4:84-96.
44. Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, Pes GM, Rosati G (1996) Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 20:1159-1170.
45. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (1994) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36:348-355.
46. Smith DW, Friedmann T (2004) Discrepant effects of culture conditions on survival and function of dopaminergic neurons. NeuroReport 15:1025-1028.
47. Tompkins AJ, Burwell LS, Digerness SB, Zaragoza C, Holman WL, Brookes PS (2006) Mitochondrial dysfunction in cardiac ischemia-reperfusion injury: ROS from complex I, without inhibition. Biochim Biophys Acta 1762:223-231.
48. Trounce IA, Kim YL, Jun AS, Wallace DC (1996) Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol 264:484-509.
49. Viswanath V, Wu Y, Boonplueang R, Chen S, Stevenson FF, Yantiri F, Yang L, Beal MF, Andersen JK (2001) Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced Parkinson's disease. J Neurosci 21:9519-9528.
50. Yadava N, Houchens T, Potluri P, Scheffler IE (2004) Development and characterization of a conditional mitochondrial complex I assembly system. J Biol Chem 279:12406-12413.
51. Zeevalk GD, Manzino L, Sonsalla PK, Bernard LP (2007) Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. Exp Neurol 203:512-520.